What AI says about Biocon Biologics

Biocon Biologics develops and commercializes affordable biosimilars—insulins, monoclonal antibodies, and conjugated recombinant proteins—to broaden access to life-saving biologic therapies and improve patient outcomes worldwide. It operates in over 100 countries with a portfolio of about 20 biosimilars (10 commercialized) and has delivered 9.2 billion doses of insulin since 2004, benefiting over 6 million patients annually. The company emphasizes health equity and ESG, and has achieved major milestones including U.S. FDA approvals for interchangeable biosimilars and, via acquisition, the global biosimilars business of Viatris to become a fully integrated biosimilars leader.